Patent Number: 8,575,208

Title: Inhibitors of serine proteases

Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

Inventors: Farmer; Luc (Foxborough, MA), Bethiel; Randy Scott (Lexington, MA), Jacobs; Dylan (Everett, MA), Perni; Robert B. (Marlborough, MA), Maxwell; John (Hingham, MA), Cottrell; Kevin (Cambridge, MA), Halas; Summer (Seattle, WA)

Assignee: Vertex Pharmaceuticals Incorporated

International Classification: A61K 31/4025 (20060101); C07D 207/08 (20060101)

Expiration Date: 1/05/12017